InflaMab

N/A

Report date: 2025/03/20 15:31:09

Base Information

Drug NameInflaMab
Drug Alias NameNLRP3 inflammasome inhibitor (Santen/Ulster University/Massachusetts Eye & Ear Infirmary)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsNACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsGlaucoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of Ulster
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of UlsterSanten Pharmaceutical Co LtdMassachusetts Eye And Ear
Inactive CompaniesN/A
Active IndicationsGlaucoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A